These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24089207)

  • 1. Cancer: Killing from the inside.
    Saftig P; Sandhoff K
    Nature; 2013 Oct; 502(7471):312-3. PubMed ID: 24089207
    [No Abstract]   [Full Text] [Related]  

  • 2. It takes a CAD to kill a tumor cell with a LMP.
    Gulbins E; Kolesnick RN
    Cancer Cell; 2013 Sep; 24(3):279-81. PubMed ID: 24029224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase.
    Petersen NH; Olsen OD; Groth-Pedersen L; Ellegaard AM; Bilgin M; Redmer S; Ostenfeld MS; Ulanet D; Dovmark TH; Lønborg A; Vindeløv SD; Hanahan D; Arenz C; Ejsing CS; Kirkegaard T; Rohde M; Nylandsted J; Jäättelä M
    Cancer Cell; 2013 Sep; 24(3):379-93. PubMed ID: 24029234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drugs targeting sphingolipid metabolism.
    Bhabak KP; Arenz C
    Handb Exp Pharmacol; 2013; (215):187-96. PubMed ID: 23579456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicinal chemistry aspects of drug targets in sphingolipid metabolism.
    Nussbaumer P
    ChemMedChem; 2008 Apr; 3(4):543-51. PubMed ID: 18061920
    [No Abstract]   [Full Text] [Related]  

  • 6. Low molecular weight proteins in secondary lysosomes as activators of different sphingolipid hydrolases.
    Mraz W; Fischer G; Jatzkewitz H
    FEBS Lett; 1976 Aug; 67(1):104-9. PubMed ID: 8337
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitors of the sphingomyelin cycle: Sphingomyelin synthases and sphingomyelinases.
    Adada M; Luberto C; Canals D
    Chem Phys Lipids; 2016 May; 197():45-59. PubMed ID: 26200918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel chemotherapeutic drugs in sphingolipid cancer research.
    Canals D; Hannun YA
    Handb Exp Pharmacol; 2013; (215):211-38. PubMed ID: 23579458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.
    Canals D; Perry DM; Jenkins RW; Hannun YA
    Br J Pharmacol; 2011 Jun; 163(4):694-712. PubMed ID: 21615386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional inhibitors of acid sphingomyelinase (FIASMAs).
    Kornhuber J; Tripal P; Gulbins E; Muehlbacher M
    Handb Exp Pharmacol; 2013; (215):169-86. PubMed ID: 23579455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of acid sphingomyelinase disrupts LYNUS signaling and triggers autophagy.
    Justice MJ; Bronova I; Schweitzer KS; Poirier C; Blum JS; Berdyshev EV; Petrache I
    J Lipid Res; 2018 Apr; 59(4):596-606. PubMed ID: 29378782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical tools to investigate sphingolipid metabolism and functions.
    Delgado A; Casas J; Llebaria A; Abad JL; Fabriás G
    ChemMedChem; 2007 May; 2(5):580-606. PubMed ID: 17252619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sphingolipids in the transport of prosaposin to the lysosomes.
    Lefrancois S; Michaud L; Potier M; Igdoura S; Morales CR
    J Lipid Res; 1999 Sep; 40(9):1593-603. PubMed ID: 10484606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.
    Holman DH; Turner LS; El-Zawahry A; Elojeimy S; Liu X; Bielawski J; Szulc ZM; Norris K; Zeidan YH; Hannun YA; Bielawska A; Norris JS
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):231-42. PubMed ID: 17429631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.
    Lu Z; Li Y; Syn WK; Wang Z; Lopes-Virella MF; Lyons TJ; Huang Y
    Am J Physiol Endocrinol Metab; 2020 Feb; 318(2):E131-E144. PubMed ID: 31821039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR.
    Aoyama Y; Sobue S; Mizutani N; Inoue C; Kawamoto Y; Nishizawa Y; Ichihara M; Kyogashima M; Suzuki M; Nozawa Y; Murate T
    Biochem Biophys Res Commun; 2017 Apr; 486(2):551-557. PubMed ID: 28322796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic targets for atherosclerosis in sphingolipid metabolism.
    Yu Z; Peng Q; Huang Y
    Clin Sci (Lond); 2019 Mar; 133(6):763-776. PubMed ID: 30890654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of sphingolipids in apoptin-induced cell killing.
    Liu X; Zeidan YH; Elojeimy S; Holman DH; El-Zawahry AM; Guo GW; Bielawska A; Bielawski J; Szulc Z; Rubinchik S; Dong JY; Keane TE; Tavassoli M; Hannun YA; Norris JS
    Mol Ther; 2006 Nov; 14(5):627-36. PubMed ID: 16926120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomal accumulation of cholesterol and sphingomyelin: evidence for inhibition of acid sphingomyelinase.
    Bhuvaneswaran C; Venkatesan S; Mitropoulos KA
    Eur J Cell Biol; 1985 May; 37():98-106. PubMed ID: 2992980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological evaluation of sphingomyelin analogues as inhibitors of sphingomyelinase.
    Taguchi M; Goda K; Sugimoto K; Akama T; Yamamoto K; Suzuki T; Tomishima Y; Nishiguchi M; Arai K; Takahashi K; Kobori T
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3681-4. PubMed ID: 14552757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.